LifeScience Weekly Digest: Key Industry Updates (13th – 17th January) 

JP Morgan Week featured notable developments in drugs, devices, diagnostics, and digital health. Johnson & Johnson paid $14.6 billion for Intra-Cellular Therapies, bolstering its neuroscience portfolio with CAPLYTA® and a strong mental health pipeline. Eli Lilly invested $2.5 billion in Scorpion Therapeutics’ PI3Kα inhibitor for hormone-positive breast cancer, while Bausch + Lomb expanded ophthalmology with … Read more

Eli Lilly Shakes Up JPM25 with $2.5B Scorpion Buyout in Breast Cancer Battle

Eli Lilly kicked off the 2025 J.P. Morgan Healthcare Conference with a strategic acquisition of Scorpion Therapeutics, securing its PI3Kα pipeline for up to $2.5 billion in upfront payments and milestones. The deal marks a bold move in Lilly’s quest to compete with Novartis and Roche in the lucrative breast cancer market. A Renewed Push … Read more

Johnson & Johnson Steals the Spotlight at JPM Conference with $14.6B Intra-Cellular Therapies Acquisition

On Monday, Johnson & Johnson (J&J) made headlines at the J.P. Morgan Healthcare Conference by announcing its agreement to acquire Intra-Cellular Therapies, a pioneering biotech company specializing in treatments for brain diseases. The deal, valued at $132 per share or approximately $14.6 billion, marks the largest biotechnology acquisition since early 2023. A Strategic Play in … Read more

Transcarent paying $621M to acquire health benefits navigator Accolade 

Transcarent has announced plans to acquire Accolade for $621 million, marking a significant step toward its mission of delivering affordable and high-quality healthcare solutions. The acquisition will combine Transcarent’s innovative WayFinding and care solutions with Accolade’s personalized healthcare platform, creating a unified and comprehensive healthcare experience for users.  This collaboration aims to enhance accessibility to … Read more

CorroHealth Acquired Revenue Cycle Management Business from Navient

CorroHealth has finalized its acquisition of the healthcare revenue cycle management (RCM) business from Navient’s Xtend Healthcare, significantly expanding its capabilities in revenue cycle management consultancy and technology. This strategic move enhances CorroHealth’s RCM offerings, introducing multichannel patient engagement capabilities that were previously missing from its suite of services. By adding these capabilities, CorroHealth strengthens … Read more